Saturday 17 October 2026
Export PTHS’s income statement to Excel — free account
Pelthos Therapeutics Inc.
PTHS Healthcare Biotechnology
In the quarter to June 2026, EPS fell 23.1%, free cash flow fell 1,615.0% and total debt rose 2,692.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
20.15
0.11
−0.54%
Follow PTHS
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | — | — | — | — |
P/S ratio |
0.00 | — | — | — | — |
Altman Z-Score |
(0.75) | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
(1.47) | — | — | — | — |
P/FCF ratio |
0.00 | — | — | — | — |
P/Operating CF |
(9.32) | — | — | — | — |
P/B ratio |
1.50 | — | — | — | — |
Price to Tangible BV |
0.00 | — | — | — | — |
EV/Sales |
0.00 | — | — | — | — |
EV/EBITDA |
0.00 | — | — | — | — |
EV/Operating CF |
(3.28) | — | — | — | — |
EV/FCF |
(3.28) | — | — | — | — |
Quick Ratio |
1.03 | 0.13 | 0.01 | 0.01 | 0.00 |
Current Ratio |
2.05 | 0.34 | 0.01 | 0.01 | 0.00 |
Net Debt/EBITDA |
(0.45) | (0.24) | (0.13) | (0.22) | 0.00 |
Debt/Assets |
24.11% | 159.68% | 987.97% | 980.76% | 0.00% |
Debt/Equity |
0.81 | (0.81) | (0.15) | (0.15) | 0.00 |
Asset Turnover |
0.25 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.52 | 0.73 | 0.13 | 0.64 | 2.68 |
Capex/Depreciation |
(0.04) | 0.00 | 0.00 | 0.00 | — |
Interest Coverage |
(10.77) | (9.63) | (13.23) | (16.51) | (2,796.67) |
| (239.55%) | 173.72% | 145.42% | 66.57% | 0.00% | |
| (65.75%) | (1,085.71%) | (9,743.63%) | (8,924.14%) | 0.00% | |
ROIC |
(38.76%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(117.07%) | 293.11% | 114.53% | 66.33% | 23.07% |
Average Days of Receivables |
192.51 | — | — | — | — |
Research and Development Expense of Revenue |
7.31% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
252.77% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.49 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
32.52% | 0.00% | 0.00% | 0.00% | — |
Graham Net Nets |
(0.65) | — | — | — | — |
Graham Number |
0.00 | — | — | — | — |
Earnings Yield |
(74.55%) | — | — | — | — |
Free Cash Flow Yield |
(38.75%) | — | — | — | — |
Revenue per Share |
8.93 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(12.01) | (10.39) | (7.68) | (36.03) | 0.00 |
Capex per Share |
(0.05) | 0.00 | 0.00 | 0.00 | — |
Free Cash Flow per Share |
(12.07) | (10.39) | (7.68) | (36.03) | 0.00 |
Cash per Share |
9.58 | 0.92 | 0.75 | 1.27 | — |
Shareholders Equity per Share |
20.68 | (4.87) | (50.47) | (85.21) | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
20.68 | (4.87) | (50.47) | (85.21) | 0.00 |
Free Cash Flow |
(22.69) | (5.79) | (0.98) | (1.57) | (1.59) |
Working Capital |
27.42 | (2.71) | (6.44) | (3.71) | (2.58) |
Capital Expenditures |
(0.10) | — | — | — | — |
Net Current Asset Value |
(38.11) | (2.71) | (6.44) | (3.71) | (3.68) |
EV/EBIT |
0.00 | — | — | — | — |
Capex to Sales |
0.01 | — | — | — | — |
Price to Operating Income |
0.00 | — | — | — | — |
| Other line items | |||||
Depreciation/Fixed assets |
0.27 | 0.00 | 0.00 | 0.00 | — |
Cash ROIC |
(25.68%) | 38,613.33% | 18.18% | 50.37% | 43.28% |
Accounts Receivable Turnover |
0.00 | — | — | — | — |
Accounts Payable Turnover |
1.63 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
0.00 | — | — | — | — |
Average Days of Payables |
273.29 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
2,157.60 | — | — | — | — |
Average Payables |
2.44 | 3.26 | 3.81 | 2.79 | — |
Average Assets |
65.88 | 0.73 | 0.08 | 0.03 | — |
Average Common Equity |
18.08 | (4.58) | (5.08) | (3.69) | — |
Columns are period end dates